Floatz Rating
CCC55/100
Confidence
Indicative
Sponsor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
45High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07366658CT.gov Safety, Tolerability and Preliminary Efficacy of NEUK203-13 in Refractory Neuroendocrine Tumor Patients | — | Not Yet Recruiting | — | — | — |
NCT04119024CT.gov Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors | — | Recruiting | — | — | — |
NCT04102436CT.gov Non-Viral TCR Gene Therapy | — | Withdrawn | — | — | — |
NCT04848337CT.gov Pembrolizumab and Lenvatinib in Advanced/Metastatic Neuroendocrine Prostate Cancer | — | Active Not Recruiting | — | — | — |
NCT03935893CT.gov Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers | — | Active Not Recruiting | — | — | — |
NCT03412877CT.gov Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer | — | Recruiting | — | — | — |
NCT02628067CT.gov Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) | — | Active Not Recruiting | — | — | — |
NCT02402920CT.gov Pembrolizumab and Concurrent Chemoradiotherapy or Radiation Therapy in Treating Patients With Small Cell Lung Cancer | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Neuroendocrine Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Cyclophosphamide (this asset) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | P2 | CCC · 55 |
| Irinotecan | First Affiliated Hospital Xi'an Jiaotong University | P4 | BB |
| Cabozantinib | Fox Chase Cancer Center | P3 | BB |
| Fluorouracilum | ITM Solucin GmbH | P3 | BB |
| Everolimus | Exelixis | P3 | BB |
| Oxodotreotide | Fundación de investigación HM | P3 | BB |
| Surufatinib | Shanghai Changzheng Hospital | P3 | BB |
| Carboplatin | First Affiliated Hospital Xi'an Jiaotong University | P4 | B |
| L-Cysteinamide, D-Phenylalanyl-L-Cysteinyl-L-Phenylalanyl-D-Tryptophyl-L-Lysyl-L-Threonyl-N-(2-Hydroxy-1-(Hydroxymethyl)Propyl)-, Cyclic (2->7)-Disulfide, (R-(R*,R*))- | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | P4 | B |
+42 more in the Neuroendocrine Neoplasm cohort
Other indications for Cyclophosphamide
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Adult Acute Lymphoblastic Leukemia | — | P4 | BBB · 79 |
| Mycosis Fungoides | — | P4 | BBB · 78 |
| B-Cell Childhood Acute Lymphoblastic Leukemia | — | P3 | BBB · 78 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Cyclophosphamide in Neuroendocrine Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/cyclophosphamide-neuroendocrine-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →